Pre-market hot trades in US stocks: Celsius rose 10.85% in pre-market; Atlantic fell 7.98% in pre-market

Pre-market Hot Trades in US Stocks Celsius Holdings is up 10.85% in pre-market trading. Based on recent key news: On May 7, Rothschild & Co analyst Charlie Higgs initiated coverage on Celsius Holdings with a neutral rating and set a target price of $47. This move may attract market attention to the stock, driving its price up. Source: MarketBeat On May 4, MarketBeat noted that although Celsius Holdings currently holds a moderate buy rating among analysts, top analysts believe there are five other stocks that are more worthy of investment. This may lead some investors to reassess their investment strategies. Source: MarketBeat The market's concerns about AI technology are affecting investor sentiment. Atlantic is down 7.98% in pre-market trading. There has been no significant news recently; trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news Top Gainers in Pre-market US Stocks Global Engine is up 56.23% in pre-market trading. Based on recent news, On May 6, Global Engine Group Holding Ltd. announced a significant breakthrough in new technology research and development. This news boosted market confidence, leading to a substantial increase in stock price. On May 5, the company's quarterly financial report showed that its revenue and profit exceeded market expectations, further enhancing investor confidence and causing the stock price to rise. On May 4, analysts generally raised their ratings on Global Engine, believing the company has enormous growth potential in the future, which also positively impacted the stock price. The market reacted positively to the new technology research and development and financial report performance. Agilon Health is up 49.35% in pre-market trading. Based on recent key news: On May 6, Agilon Health reported a net income of $49 million for the first quarter, far exceeding the market expectation of $11.6 million. Adjusted EBITDA was $54 million, also higher than the expected $34.9 million. This performance drove a significant increase in stock price. Source: Reuters On May 4, JP Morgan downgraded Agilon Health's rating from "neutral" to "underweight," with a target price of $21. The brokerage pointed out that healthcare utilization remains persistently high, and execution risks are still considerable, leading to a 7.5% drop in stock price. Source: Reuters On May 6, Agilon Health released content via Business Wire indicating that improvements in its data and forecasting capabilities, as well as operational process enhancements, have driven an increase in risk scores and effective management of healthcare costs. These positive operational improvements support the company's future financial performance Source: Business Wire The healthcare industry faces challenges of high medical utilization rates. Aspire Biopharma, pre-market up 37.47%, has no significant news recently. Trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation